Delta Sleep-Inducing Peptide (DSIP) 10 mg

Delta Sleep-Inducing Peptide (DSIP) is a high-purity, synthetic neuropeptide designed exclusively for laboratory research purposes. Composed of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, DSIP has a molecular weight of 848.83 g/mol and is provided as a lyophilized (freeze-dried) powder in a sterile 3ml vial. This research-grade peptide, with a purity of ≥97% (verified by third-party HPLC analysis), is intended for in vitro studies exploring its physiological and endocrine effects, particularly in sleep regulation, stress response, and neuroendocrine signaling. DSIP is not approved for human or veterinary use and should only be handled by qualified professionals in controlled laboratory settings.

• Purity: ≥97% purity, confirmed by third-party high-performance liquid chromatography (HPLC) and mass spectrometry (MS) testing.
• Form: Lyophilized white powder, supplied in a sterile 3ml vial with a butyl rubber stopper for multiple penetrations while maintaining a secure seal.
• Quantity: 10 mg per vial.
• CAS Number: 62568-57-4.
• Salt Form: Acetate.
• Solubility: Reconstitutes easily in bacteriostatic water or sterile saline solution (1ml/vial recommended).
• Storage: Store at -20°C to maintain stability and integrity.
• Applications: Suitable for biochemical, neurophysiological, and immunological research.
• Restrictions: For laboratory research use only. Not for human consumption, medical, veterinary, or household applications.

First isolated in the 1970s from the cerebral venous blood of rabbits during slow-wave sleep, DSIP is a naturally occurring neuropeptide found in the hypothalamus, limbic system, pituitary, and various peripheral tissues. It has garnered significant interest in research for its potential to modulate key physiological processes, including:

• Sleep Regulation: DSIP is renowned for its ability to promote deep, slow-wave sleep (delta sleep) and stabilize sleep-wake cycles. Studies in animal models, such as rabbits and rats, have shown DSIP’s influence on delta wave activity, non-REM sleep, and circadian rhythm stability. In human studies with chronic insomniacs, DSIP has demonstrated a normalizing effect on sleep onset latency and sleep efficiency, though results vary.

• Stress Response: Preclinical research suggests DSIP may enhance adaptive stress responses by modulating cortisol, melatonin, and growth hormone secretion. It interacts with hypothalamic and pituitary pathways, potentially stabilizing brainwave activity and autonomic nervous system regulation.

• Antioxidant Properties: DSIP has shown promise as a potent antioxidant by preserving normal mitochondrial function and reducing free radical production. In vitro studies indicate it supports oxidative phosphorylation, even under hypoxic conditions, which could have implications for research into conditions like stroke or ischemia.

• Pain and Withdrawal Management: DSIP has been studied for its antinociceptive effects in animal models, reducing pain responses in tail-pinch and hot-plate tests, possibly via opioid receptor interactions. Clinical studies involving 107 patients with alcohol or opiate addiction reported significant improvement in withdrawal symptoms (97% for alcohol, 87% for opiates).

• Other Research Applications: DSIP is being explored for its effects on myocardial contractility, blood pressure normalization, muscle recovery, and as an adjuvant in cancer research. A study in mice showed a 2.6-fold decrease in tumor development and a 22.6% reduction in chromosomal defects when DSIP was administered prophylactically.

To prepare DSIP for research use:

• Gather Materials: DSIP 10 mg vial, bacteriostatic water or sterile saline, syringe, and alcohol swabs.
• Disinfect: Clean the vial’s rubber stopper and reconstitution solution with alcohol swabs.
• Reconstitute: Using a syringe, inject 1ml of bacteriostatic water or sterile saline into the vial. Gently swirl (do not shake) until the powder is fully dissolved.
• Storage: Reconstituted DSIP should be stored at 2–8°C and used within a short period to maintain stability.

For in vitro or animal studies, typical starting doses are around 100 mcg per administration, often given at night (approximately three hours before the subject’s rest period). Research protocols have tested doses up to 21.4 mcg/kg daily for up to 14 days. Microdosing (sub-therapeutic levels) may be explored to minimize adverse effects while studying benefits related to sleep, stress, or withdrawal management. Researchers should consult current literature for precise dosing and cycling protocols, as recommendations may evolve.

• Intended Use: DSIP is strictly for laboratory research and not for human or animal consumption.
• Handling: Must be handled by licensed professionals in a controlled laboratory environment.
• Legal Disclaimer: This product is not approved by the FDA for any medical, diagnostic, or therapeutic use. Bodily introduction into humans or animals is prohibited by law.

Studies indicate that CJC-1295 and Ipamorelin are generally well-tolerated, with mild side effects including:

Injection site reactions (redness, itching, or pain)
Headaches, nausea, or lightheadedness
Water retention or flushing (rare with recommended doses)
Low-purity peptides may increase side effect risks, so sourcing from reputable vendors with lab-tested products is critical. Long-term effects remain understudied, necessitating cautious research protocols.

DSIP is a versatile research tool for investigating:

• Neuroendocrine signaling and hormone regulation (cortisol, melatonin, growth hormone).
• Brainwave activity and sleep architecture (delta wave and REM/NREM cycles).
• Stress adaptation and autonomic nervous system modulation.
• Antioxidant mechanisms and mitochondrial function under stress or hypoxia.
• Pain perception and opioid receptor interactions.
• Potential therapeutic roles in addiction, depression, or cancer models.

DSIP 10 mg is manufactured in cGMP-certified facilities and undergoes rigorous third-party testing to ensure purity, potency, and consistency. Each batch is accompanied by a Certificate of Analysis (COA) and HPLC reports, guaranteeing research-grade quality.

• Packaging: Securely packed in a tamper-evident, sterile 3ml vial with an aluminum flip-top.
• Shipping: Available for immediate dispatch with professional logistics to ensure on-time delivery. Products are shipped in temperature-controlled conditions to maintain integrity.
• Customization: Bulk orders (20+ vials) and custom synthesis options are available upon request. Contact the supplier for competitive quotations and tailored solutions.

DSIP 10 mg is sold exclusively for scientific research and development purposes. It is not intended for use as a drug, supplement, or cosmetic product. All information provided is for educational purposes only and has not been evaluated by the FDA. Researchers are responsible for adhering to local regulations and ethical guidelines when using this product.